CA3242202A1 - IONIC LIQUID-BASED FORMULATIONS FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL DISEASES - Google Patents
IONIC LIQUID-BASED FORMULATIONS FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL DISEASESInfo
- Publication number
- CA3242202A1 CA3242202A1 CA3242202A CA3242202A CA3242202A1 CA 3242202 A1 CA3242202 A1 CA 3242202A1 CA 3242202 A CA3242202 A CA 3242202A CA 3242202 A CA3242202 A CA 3242202A CA 3242202 A1 CA3242202 A1 CA 3242202A1
- Authority
- CA
- Canada
- Prior art keywords
- ionic
- prevention
- treatment
- liquid
- neurological diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PT117761 | 2022-01-26 | ||
| PT11776122 | 2022-01-26 | ||
| PCT/IB2023/050671 WO2023144742A1 (en) | 2022-01-26 | 2023-01-26 | Ionic-liquid-based formulations for the prevention or treatment of neurological diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3242202A1 true CA3242202A1 (en) | 2023-08-03 |
Family
ID=85936842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3242202A Pending CA3242202A1 (en) | 2022-01-26 | 2023-01-26 | IONIC LIQUID-BASED FORMULATIONS FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL DISEASES |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12514845B2 (https=) |
| EP (1) | EP4469044B1 (https=) |
| JP (1) | JP2025504768A (https=) |
| CN (1) | CN118524836B (https=) |
| CA (1) | CA3242202A1 (https=) |
| WO (1) | WO2023144742A1 (https=) |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012201058A1 (en) | 2003-08-29 | 2012-03-15 | President And Fellows Of Harvard College | Inhibitors of cellular necrosis |
| KR20080051246A (ko) | 2006-12-05 | 2008-06-11 | (주)에스에이치제약 | 뇌신경계 질환의 예방 또는 치료용 및 ｎａｄｐｈ 산화효소활성억제용 약학적 조성물 |
| WO2010078258A1 (en) | 2008-12-29 | 2010-07-08 | The Board Of Trustees Of The University Of Alabama | Compounds comprising two or more biologically functional ions and method of treating parkinson's disease |
| EP2554163A4 (en) | 2010-03-26 | 2013-07-17 | Univ Hokkaido Nat Univ Corp | THERAPEUTIC ACTIVE FOR NEURODEGENERATIVE DISEASES |
| KR101411838B1 (ko) | 2011-02-09 | 2014-06-27 | 부산대학교 산학협력단 | 피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도 |
| US8673956B2 (en) | 2011-12-02 | 2014-03-18 | Board Of Trustees Of The University Of Alabama | Imido-acid salts and methods of use |
| CN103330708B (zh) | 2013-07-23 | 2014-11-26 | 苏州大学 | 5-(3’，5’-二甲氧基苯甲撑基)-2-硫代-咪唑-4-酮在制备治疗脑血管疾病的药物中的应用 |
| WO2015129527A1 (ja) | 2014-02-27 | 2015-09-03 | 株式会社メドレックス | プラミペキソールを含有する神経変性疾患の治療用貼付剤 |
| EP3129102B1 (en) | 2014-04-07 | 2025-06-18 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Iodonium analogs as inhibitors of nadph oxidases and other flavin dehydrogenases; formulations thereof; and uses thereof |
| JP2015227329A (ja) | 2014-05-09 | 2015-12-17 | サントリーホールディングス株式会社 | メトキシフラボンを含むＮＯＸ阻害剤及びＮＦκＢ阻害剤 |
| WO2018129421A1 (en) | 2017-01-09 | 2018-07-12 | Genervon Biopharmaceuticals, LLC | A promising drug candidate for parkinson's disease |
| WO2019023448A1 (en) | 2017-07-26 | 2019-01-31 | Emory University | INHIBITORS OF NADPH OXIDASE AND THEIR USE |
| US20190135741A1 (en) | 2017-11-09 | 2019-05-09 | Nacuity Pharmaceuticals, Inc. | Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress |
| US10716866B2 (en) | 2018-03-29 | 2020-07-21 | Generoath Co., Ltd | Pharmaceutical composition comprising AIMP2-DX2 for preventing or treating neuronal diseases and use thereof |
| KR20200022193A (ko) | 2018-08-22 | 2020-03-03 | 한림대학교 산학협력단 | 결핵성 흉막 섬유증 예방 또는 치료용 약학 조성물 |
| WO2020205937A1 (en) | 2019-04-01 | 2020-10-08 | Emory University | Hyaluronic acid nanoparticles comprising nadph oxidases inhibitors and uses in treating cancer |
| CN111138376A (zh) | 2019-12-24 | 2020-05-12 | 中山大学 | 一种3,5-二取代苯基-1,2,4-噁二唑衍生物及其制备方法和应用 |
| US12552779B2 (en) * | 2020-07-10 | 2026-02-17 | Duksung Women's University Industry-Academic Cooperation Foundation | 1-alkyl-5-arylidene-2-selenoxoimidazolidine-4-on and derivative thereof, preparation method therefor, and composition comprising same for preventing, alleviating or treating neurodegenerative diseases |
-
2023
- 2023-01-26 EP EP23715590.8A patent/EP4469044B1/en active Active
- 2023-01-26 CA CA3242202A patent/CA3242202A1/en active Pending
- 2023-01-26 CN CN202380015838.5A patent/CN118524836B/zh active Active
- 2023-01-26 US US18/725,257 patent/US12514845B2/en active Active
- 2023-01-26 JP JP2024539747A patent/JP2025504768A/ja active Pending
- 2023-01-26 WO PCT/IB2023/050671 patent/WO2023144742A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4469044B1 (en) | 2026-04-08 |
| CN118524836B (zh) | 2026-03-27 |
| WO2023144742A1 (en) | 2023-08-03 |
| EP4469044A1 (en) | 2024-12-04 |
| CN118524836A (zh) | 2024-08-20 |
| US20240415815A1 (en) | 2024-12-19 |
| JP2025504768A (ja) | 2025-02-19 |
| US12514845B2 (en) | 2026-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4267196A4 (en) | TREATMENT OF NEUROLOGICAL DISEASES | |
| AU2022298746A1 (en) | Beta-lactam derivatives for the treatment of diseases | |
| EP4100406A4 (en) | COMPOSITIONS FOR THE TREATMENT OF OCULAR DISEASES | |
| AU2024211867A1 (en) | 1-amino-4-phenylphthalazine derivatives useful for the treatment of neurodegenerative diseases | |
| AU2024216821A1 (en) | Rifabutin analogs for the treatment of bacterial diseases | |
| EP4217355A4 (en) | AGENTS FOR TREATING DISEASES BY INHIBITING FOXO1 | |
| CA3242202A1 (en) | IONIC LIQUID-BASED FORMULATIONS FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL DISEASES | |
| EP3914263A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF EYE DISEASES AND DISORDERS | |
| WO2023009817A3 (en) | Phosphate prodrugs of cannabinoids | |
| EP4048678A4 (en) | COMPOUNDS AND COMPOSITIONS FOR TREATING PARASITIC DISEASES | |
| HK40106144A (en) | Compositions for the treatment of ebv associated diseases or conditions | |
| CA3300058A1 (en) | Treatment of neurological diseases | |
| HK40108083A (en) | Direct transdifferentiation for treatment of neurological disease | |
| CA3262432A1 (en) | Compositions for the treatment of cftr-mediated diseases | |
| HK40126024A (en) | Compositions for the treatment of cftr-mediated diseases | |
| HK40128051A (en) | Compositions for the treatment of disease | |
| CA3278922A1 (en) | Rifabutin analogs for the treatment of bacterial diseases | |
| CA3287576A1 (en) | Compounds for the treatment and prevention of viral diseases | |
| AU2021902146A0 (en) | Compositions for the Treatment of Diseases and Conditions | |
| CA3280282A1 (en) | Compositions and formulations for the prevention, treatment, and improvement of skin diseases, conditions, and disorders | |
| CA3305907A1 (en) | Compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| AU2024352869A1 (en) | Compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| CA3279062A1 (en) | 1-amino-4-phenylphthalazine derivatives useful for the treatment of neurodegenerative diseases | |
| AU2020901573A0 (en) | Compositions for the Treatment of Diseases and Conditions | |
| CA3271680A1 (en) | Methods and compositions for the treatment of neurodegenerative disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20240702 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240702 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R125 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMMON REPRESENTATIVE APPOINTED Effective date: 20240702 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241106 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - SMALL Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250108 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250108 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250108 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - SMALL Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251223 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251223 |